⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276906 | 0.69 | — | — | |
| SCHEMBL20743619 | 0.67 | LOXL2 (0.43) | — | |
| SCHEMBL24579547 | 0.65 | HCAR2 (0.65) | — | |
| SCHEMBL8134472 | 0.63 | — | — | |
| SCHEMBL24442287 | 0.63 | — | — | |
| SCHEMBL2012248 | 0.62 | — | — | |
| SCHEMBL883790 | 0.62 | — | — | |
| SCHEMBL22322736 | 0.62 | — | — | |
| SCHEMBL6823175 | 0.62 | — | — | |
| SCHEMBL128301 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-20240270739-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-08-15 | — | — | US | disclosed |
| WO-2024151346-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2023-12-07 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230286978-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4234566-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI Shenzhen (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014099695-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014099694-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014067962-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014060381-A1 | HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014047662-A2 | INDAZOLE DERIVATIVES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-1902024-B1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011087738-A2 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2100941-A2 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-09-16 | — | — | EP | disclosed |